Major life sciences companies have become regular litigants. Edwards Lifesciences brought a flagship heart valve dispute against Meril Life Sciences at the court's launch. Roche settled with Tandem in June 2025. Other active parties include MED-EL, 10x Genomics, Novartis, Abbott, and Dexcom, alongside generics and biosimilars manufacturers. The European Patent Office and Court of Justice of the European Union have aligned their standards with UPC practice, particularly on inventive step analysis using the problem-solution approach.
The UPC's trajectory reflects a shift from initial pharmaceutical industry skepticism about pan-European patent revocation in an untested system. Case filings accelerated from 160 by end-2023 to 700 by January 2025, signaling growing confidence. The court has maintained a 50:50 revocation win rate and delivered settlements, establishing itself as faster and more efficient than parallel national proceedings. Medical device companies have embraced the forum more readily than pharmaceutical innovators, though the UPC is now viewed as a strategic imperative for coordinated enforcement. Practitioners should expect continued growth in complex multi-jurisdictional disputes and should reassess European IP strategies accordingly.